By: IPP Bureau
Last updated : June 05, 2026 6:06 pm
Wanbury Limited, a leading pharmaceutical company, has reported a strong financial performance for FY26, with profit after tax (PAT).
The company has more than doubled its profit on the back of improved operational efficiencies, favorable product mix, and continued momentum in its API and formulations businesses.
For FY26, the company's PAT surged 117% year-on-year to Rs. 66.1 crore, while PAT margin expanded by 509 basis points to 10.2%. Earnings per share (EPS) more than doubled to Rs. 20.55 from Rs. 9.32 in the previous year, reflecting robust bottom-line growth.
EBITDA for the year increased 34.9% YoY to Rs. 107.7 crore, supported by revenue growth, enhanced product yields, procurement efficiencies, process optimization, and better operating leverage.
Despite geopolitical disruptions affecting exports, Wanbury maintained profitability in the fourth quarter. Revenue from operations for Q4 FY26 stood at Rs. 164.6 crore, compared with Rs. 172 crore in the corresponding quarter last year, impacted by the West Asia crisis that disrupted API exports during March 2026.
Operationally, Wanbury achieved several milestones during the year. The company launched a new Anaesthetic API from its Tanuku facility following completion of a capital expenditure program, with commercial dispatches to Europe commencing in February 2026.
The company also strengthened its product pipeline with upcoming specialty APIs including Dextromethorphan HBr, Rivaroxaban, and Sitagliptin.
Mohan Rayana, Director, Wanbury Limited, said, "FY26 was an important year for Wanbury. We strengthened business fundamentals through operational efficiencies, debottlenecking, balance sheet improvement, and expansion of our API and formulations portfolio.”